IONS

Ionis Pharmaceuticals Inc

IONS, USA

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

https://www.ionis.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IONS
stock
IONS

450,254 Shares in Ionis Pharmaceuticals, Inc. $IONS Acquired by Norges Bank MarketBeat

Read more →
IONS
stock
IONS

Can Ionis Pharmaceuticals Stock Hold Up When Markets Turn? Trefis

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$85.4678

Analyst Picks

Strong Buy

12

Buy

5

Hold

8

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

20.68

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-20.81 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-4.24 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-85.98 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

3.91

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 132.20% of the total shares of Ionis Pharmaceuticals Inc

1.

FMR Inc

(14.8333%)

since

2025/06/30

2.

Vanguard Group Inc

(10.4867%)

since

2025/06/30

3.

T. Rowe Price Investment Management,Inc.

(10.0688%)

since

2025/06/30

4.

Capital World Investors

(7.8676%)

since

2025/06/30

5.

Fidelity Growth Compy Commingled Pl S

(6.8446%)

since

2025/07/31

6.

BlackRock Inc

(6.8366%)

since

2025/06/30

7.

Bellevue Group AG

(4.927%)

since

2025/06/30

8.

BB Biotech AG Ord

(4.925%)

since

2024/12/31

9.

Fidelity Growth Company Fund

(4.833%)

since

2025/07/31

10.

Wellington Management Company LLP

(3.9813%)

since

2025/06/30

11.

T. Rowe Price US Mid-Cap Growth Equity

(3.7601%)

since

2025/06/30

12.

T. Rowe Price Mid-Cap Growth

(3.7532%)

since

2025/07/31

13.

Deep Track Capital, LP

(3.0689%)

since

2025/06/30

14.

Vanguard Total Stock Mkt Idx Inv

(2.9907%)

since

2025/07/31

15.

American Funds SMALLCAP World A

(2.8641%)

since

2025/06/30

16.

State Street Corp

(2.8423%)

since

2025/06/30

17.

Vanguard Health Care Inv

(2.5029%)

since

2025/06/30

18.

Adage Capital Partners Gp LLC

(2.3841%)

since

2025/06/30

19.

Vanguard Small Cap Index

(2.3044%)

since

2025/07/31

20.

American Funds New Economy A

(2.0125%)

since

2025/06/30

21.

Capital Group New Economy Comp

(2.0125%)

since

2025/06/30

22.

T. Rowe Price Associates, Inc.

(1.9613%)

since

2025/06/30

23.

Tweedy, Browne Co LLC

(1.8144%)

since

2025/06/30

24.

Geode Capital Management, LLC

(1.8138%)

since

2025/06/30

25.

Two Sigma Advisers, LLC

(1.6736%)

since

2025/06/30

26.

Millennium Management LLC

(1.6623%)

since

2025/06/30

27.

American Funds Growth Fund of Amer A

(1.5064%)

since

2025/06/30

28.

Capital Group Growth Fnd of Amer Comp

(1.5064%)

since

2025/06/30

29.

Tweedy, Browne International Value Fund

(1.4747%)

since

2025/06/30

30.

Fidelity Growth Company K6

(1.4617%)

since

2025/07/31

31.

Fidelity Series Growth Company

(1.3462%)

since

2025/07/31

32.

Vanguard Small Cap Growth Index Inv

(1.299%)

since

2025/07/31

33.

Bvf Inc

(1.2004%)

since

2025/06/30

34.

T. Rowe Price U.S. Mid-Cap Gr Eq Tr-D

(1.1769%)

since

2025/06/30

35.

Vanguard Explorer Inv

(1.1428%)

since

2025/06/30

36.

Two Sigma Investments LLC

(1.122%)

since

2025/06/30

37.

SPDR® S&P Biotech ETF

(1.1086%)

since

2025/08/31

38.

UBS Group AG

(0.9595%)

since

2025/06/30

39.

Citadel Advisors Llc

(0.9379%)

since

2025/06/30

40.

Charles Schwab Investment Management Inc

(0.9334%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.6125

EPS Estimate

-1.22

EPS Difference

0.6075

Surprise Percent

49.7951%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.